Novartis' 3rd-gen kinase inhibitor tops Pfizer's Bosulif in head-to-head leukemia trial UniQure/CSL hem B gene therapy curbs bleeding in phase 3—even in patients with anti-AAV antibodies Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy J&J, Legend's anti-BCMA CAR-T keeps it consistent in phase 2 as FDA filing looms AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice Regeneron's bispecific banishes lymphoma—even in patients failed by CAR-T Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field AbbVie, Roche's fixed-duration Venclexta combos gain steam in CLL J&J links subcut BCMA bispecific to 73% response rate, plots aggressive investment Kura chalks another one up for menin inhibitors in leukemia Takeda's Iclusig pads case for new leukemia use with 5-year survival data Johnson & Johnson shores up Darzalex's myeloma lead with another subcutaneous win Incyte, Novartis eye Jakafi approval after chronic graft vs. host win CRISPR-edited CAR-T cells show enhanced activation against leukemia in mice Featured Story | By Amirah Al Idrus Tyrosine kinase inhibitors, or TKIs, were a game changer for patients with chronic myeloid leukemia. But many patients still miss out on the benefits because their cancer develops resistance, or they can’t tolerate the side effects. Novartis is working on a new drug for these patients—and its latest data look good. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus People with hemophilia B lack a protein that helps their blood clot, so they rely on lifelong infusions of that protein to manage their disease. UniQure and CSL Behring’s hemophilia B gene therapy could transform chronic care into a one-time treatment—and its latest data suggest it could work for patients considered unsuitable for gene therapy. read more By Carly Helfand Gilead Sciences is waiting for phase 3 data to show its Yescarta can help previously treated diffuse large B-cell lymphoma patients earlier in their treatment course. But, in the meantime, it’s trumpeting phase 2 stats in newly diagnosed lymphoma patients that could bode well for its forthcoming results. read more By Amirah Al Idrus Bristol Myers Squibb and bluebird bio were first to file an anti-BCMA CAR-T for approval, but Johnson & Johnson and Legend Biotech are hot on their heels. The companies unveiled the first phase 2 data for their prospect, which banished multiple myeloma in two-thirds of patients and shrank tumors in 97% of patients. read more By Carly Helfand Johnson & Johnson and AbbVie’s Imbruvica currently reigns supreme in the previously untreated chronic lymphocytic leukemia market. But newer members of its class are threatening, and both of them put up data in other cancer types that might catch the attention of CLL prescribers down the line. read more By Amirah Al Idrus CAR-T therapies have been a game changer in certain blood cancers, but they aren't a complete solution. For starters, not all patients can get CAR-T treatment, while others see their cancer worsen despite receiving it. But Regeneron’s bispecific antibody could be a new option for those patients. The drug beat cancer back in two kinds of lymphoma in a phase 1 study. read more By Carly Helfand Novartis is gunning for its third Kymriah indication, and Saturday it posted new data that just might win over regulators. But by the time the CAR-T therapy gets to tackle its new market, it may have to face down a familiar foe in Gilead Sciences' Yescarta. read more By Nick Paul Taylor Allogene Therapeutics has linked its off-the-shelf anti-BCMA CAR-T cell therapy to a 60% response rate in a phase 1 trial. The candidate is up against autologous cell therapies that have set the efficacy bar high, but Allogene has off-the-shelf advantages and levers to pull to further improve outcomes. read more By Carly Helfand Johnson & Johnson and AbbVie’s Imbruvica is the standard of care in previously untreated chronic lymphocytic leukemia (CLL). But patients need to take it indefinitely, which can be difficult, both mentally and physically. Enter Venclexta, which AbbVie and Roche are working to combine with Imbruvica for a fixed duration of treatment. read more By Nick Paul Taylor A subcutaneous formulation of Johnson & Johnson’s BCMAxCD3 bispecific antibody teclistamab has achieved a 73% overall response rate in a small trial of heavily pretreated multiple myeloma patients. read more By Amirah Al Idrus Adults with acute myeloid leukemia (AML) often beat back their cancer with front-line chemotherapy, but many patients relapse and need other options. Early data out of Kura Oncology suggest menin inhibitors could be one of those options. Its drug eliminated tumors in two patients with AML that had come back after previous treatment or hadn’t responded in the first place. read more By Carly Helfand About one-third of chronic myeloid leukemia patients don’t survive past the five-year mark, in part thanks to built-up resistance to treatment options. And that’s a stat Takeda’s trying to change with Iclusig. read more By Carly Helfand With Sanofi’s Sarclisa hitting multiple myeloma star Darzalex with its first in-class competition, Johnson & Johnson is working to convert patients to a newer, more convenient subcutaneous version of the med. And some new data just gave that mission a boost. read more By Carly Helfand Incyte and Novartis’ Jakafi already boasts an indication in acute graft vs. host disease, thanks to an approval last year. But it’s also eying a nod in the chronic form of the disease—and it may just have the data to get it done. read more By Arlene Weintraub Novartis’ CAR-T cancer therapy Kymriah can induce long-term remissions in some blood cancers, but many patients either relapse or don’t respond at all. University of Pennsylvania researchers used CRISPR-Cas9 to eliminate a protein that can stifle the activation of the cancer-killing cells, greatly improving responses in mice. read more | 